Scholarlink

Purpose of Review <p>Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Effective surveillance improves patient outcomes, but the standard modality—ultrasound (US) with or without alpha-fetoprotein (AFP)—has suboptimal sensitivity. This review evaluates the role of abbreviated MRI (AMRI) as an alternative HCC screening tool, highlighting its diagnostic performance, protocol variation, and implementation challenges.</p> Recent Findings <p>AMRI offers higher sensitivity (84–87%) than US (50–65%) for HCC detection, particularly in high-risk patients. Among AMRI protocols, non-contrast AMRI shows the highest specificity, while contrast-enhanced AMRI improves sensitivity for early-stage HCC. Ongoing trials are evaluating its role in routine surveillance and cost-effectiveness.</p> Summary <p>AMRI is a promising alternative to US for HCC surveillance, achieving superior sensitivity, especially for early-stage tumors, with shorter scan times. However, protocol variability, cost, and accessibility remain major challenges. Large-scale trials may support its clinical effectiveness and broader adoption in high-risk populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abbreviated MRI for Hepatocellular Carcinoma Screening: A Comprehensive Review

  • 期刊论文

  • 发表日期：

    2025年4月29日

查看全文
  • Ji Hye Min,
  • Young Kon Kim,
  • Woo Kyoung Jeong,
  • Bachir Taouli

摘要

Purpose of Review

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Effective surveillance improves patient outcomes, but the standard modality—ultrasound (US) with or without alpha-fetoprotein (AFP)—has suboptimal sensitivity. This review evaluates the role of abbreviated MRI (AMRI) as an alternative HCC screening tool, highlighting its diagnostic performance, protocol variation, and implementation challenges.

Recent Findings

AMRI offers higher sensitivity (84–87%) than US (50–65%) for HCC detection, particularly in high-risk patients. Among AMRI protocols, non-contrast AMRI shows the highest specificity, while contrast-enhanced AMRI improves sensitivity for early-stage HCC. Ongoing trials are evaluating its role in routine surveillance and cost-effectiveness.

Summary

AMRI is a promising alternative to US for HCC surveillance, achieving superior sensitivity, especially for early-stage tumors, with shorter scan times. However, protocol variability, cost, and accessibility remain major challenges. Large-scale trials may support its clinical effectiveness and broader adoption in high-risk populations.